Prostate cancer and elective nodal radiation therapy for cN0 and pN0-a never ending story? : Recommendations from the prostate cancer expert panel of the German Society of Radiation Oncology (DEGRO)
© 2024. The Author(s)..
For prostate cancer, the role of elective nodal irradiation (ENI) for cN0 or pN0 patients has been under discussion for years. Considering the recent publications of randomized controlled trials, the prostate cancer expert panel of the German Society of Radiation Oncology (DEGRO) aimed to discuss and summarize the current literature. Modern trials have been recently published for both treatment-naïve patients (POP-RT trial) and patients after surgery (SPPORT trial). Although there are more reliable data to date, we identified several limitations currently complicating the definitions of general recommendations. For patients with cN0 (conventional or PSMA-PET staging) undergoing definitive radiotherapy, only men with high-risk factors for nodal involvement (e.g., cT3a, GS ≥ 8, PSA ≥ 20 ng/ml) seem to benefit from ENI. For biochemical relapse in the postoperative situation (pN0) and no PSMA imaging, ENI may be added to patients with risk factors according to the SPPORT trial (e.g., GS ≥ 8; PSA > 0.7 ng/ml). If PSMA-PET/CT is negative, ENI may be offered for selected men with high-risk factors as an individual treatment approach.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:200 |
|---|---|
| Enthalten in: |
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al - 200(2024), 3 vom: 25. Feb., Seite 181-187 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Koerber, S A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
EC 3.4.21.77 |
|---|
| Anmerkungen: |
Date Completed 20.02.2024 Date Revised 22.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00066-023-02193-4 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367635542 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367635542 | ||
| 003 | DE-627 | ||
| 005 | 20240222232414.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240126s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00066-023-02193-4 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1302.xml |
| 035 | |a (DE-627)NLM367635542 | ||
| 035 | |a (NLM)38273135 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Koerber, S A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prostate cancer and elective nodal radiation therapy for cN0 and pN0-a never ending story? |b Recommendations from the prostate cancer expert panel of the German Society of Radiation Oncology (DEGRO) |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.02.2024 | ||
| 500 | |a Date Revised 22.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a For prostate cancer, the role of elective nodal irradiation (ENI) for cN0 or pN0 patients has been under discussion for years. Considering the recent publications of randomized controlled trials, the prostate cancer expert panel of the German Society of Radiation Oncology (DEGRO) aimed to discuss and summarize the current literature. Modern trials have been recently published for both treatment-naïve patients (POP-RT trial) and patients after surgery (SPPORT trial). Although there are more reliable data to date, we identified several limitations currently complicating the definitions of general recommendations. For patients with cN0 (conventional or PSMA-PET staging) undergoing definitive radiotherapy, only men with high-risk factors for nodal involvement (e.g., cT3a, GS ≥ 8, PSA ≥ 20 ng/ml) seem to benefit from ENI. For biochemical relapse in the postoperative situation (pN0) and no PSMA imaging, ENI may be added to patients with risk factors according to the SPPORT trial (e.g., GS ≥ 8; PSA > 0.7 ng/ml). If PSMA-PET/CT is negative, ENI may be offered for selected men with high-risk factors as an individual treatment approach | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a ENI | |
| 650 | 4 | |a Pelvic irradiation | |
| 650 | 4 | |a Pelvic nodal treatment | |
| 650 | 4 | |a Prostate carcinoma | |
| 650 | 4 | |a Radiotherapy | |
| 650 | 7 | |a Prostate-Specific Antigen |2 NLM | |
| 650 | 7 | |a EC 3.4.21.77 |2 NLM | |
| 700 | 1 | |a Höcht, S |e verfasserin |4 aut | |
| 700 | 1 | |a Aebersold, D |e verfasserin |4 aut | |
| 700 | 1 | |a Albrecht, C |e verfasserin |4 aut | |
| 700 | 1 | |a Boehmer, D |e verfasserin |4 aut | |
| 700 | 1 | |a Ganswindt, U |e verfasserin |4 aut | |
| 700 | 1 | |a Schmidt-Hegemann, N-S |e verfasserin |4 aut | |
| 700 | 1 | |a Hölscher, T |e verfasserin |4 aut | |
| 700 | 1 | |a Mueller, A-C |e verfasserin |4 aut | |
| 700 | 1 | |a Niehoff, P |e verfasserin |4 aut | |
| 700 | 1 | |a Peeken, J C |e verfasserin |4 aut | |
| 700 | 1 | |a Pinkawa, M |e verfasserin |4 aut | |
| 700 | 1 | |a Polat, B |e verfasserin |4 aut | |
| 700 | 1 | |a Spohn, S K B |e verfasserin |4 aut | |
| 700 | 1 | |a Wolf, F |e verfasserin |4 aut | |
| 700 | 1 | |a Zamboglou, C |e verfasserin |4 aut | |
| 700 | 1 | |a Zips, D |e verfasserin |4 aut | |
| 700 | 1 | |a Wiegel, T |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al |d 1995 |g 200(2024), 3 vom: 25. Feb., Seite 181-187 |w (DE-627)NLM012599174 |x 1439-099X |7 nnns |
| 773 | 1 | 8 | |g volume:200 |g year:2024 |g number:3 |g day:25 |g month:02 |g pages:181-187 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00066-023-02193-4 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 200 |j 2024 |e 3 |b 25 |c 02 |h 181-187 | ||